3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
5
Gynecologic
2
Gastrointestinal
2
Head & Neck
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
196
Triple Negative Breast Neoplasms
26
Neoplasm Metastasis
18
Breast Neoplasms, Male
13
Ovarian Neoplasms
9
Inflammatory Breast Neoplasms
9
Pancreatic Neoplasms
8
Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Stomach Neoplasms
5
Prostatic Neoplasms
4
Lung Neoplasms
4
Endometrial Neoplasms
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Multiple Myeloma
2
Lymphedema
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Brain Neoplasms
2
Uterine Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Interventions
pembrolizumab
14
Docetaxel
7
cemiplimab
4
avelumab
4
Trastuzumab
4
Paclitaxel
4
fludarabine
3
durvalumab
3
atezolizumab
3
Psychiatric Rehabilitation
3
Nivolumab
3
Methods
3
Gemcitabine
3
Fluorouracil
3
Early Intervention, Educational
3
Cyclophosphamide
3
Carboplatin
3
Biopsy
3
zimberelimab
2
poly ICLC
2
palbociclib
2
belinostat
2
amminedichloro(2-methylpyridine)platinum(II)
2
Tetrahydrouridine
2
Taxes
2
Standard of Care
2
Specimen Handling
2
Sirolimus
2
Radiotherapy
2
Positron-Emission Tomography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Bevacizumab
×
Breast
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled